A new treatment is effective for advanced HER2-low breast cancer
Treatment with trastuzumab deruxtecan, a combination of a targeted therapy with chemotherapy, increases progression-free survival of the disease and1
News about Aleix prat
An Hospital Clínic-IDIBAPS research project receives a CRIS Foundation grant
Aleix Prat is leading the research, which focuses on discovering new ways of diagnosing hormone receptor-positive breast cancer, as well as new thera1
Developed the first genomic test for personalized HER2+ breast cancer treatments
The new test, called HER2DX, analyzes RNA on 27 genes to predict survival outcomes and the likelihood that patients will respond to treatment.
Liquid biopsy: the most sensitive and least invasive cancer analysis technique
A study conducted at Hospital Clínic analysed the genetic profile of more than 300 patients with solid tumours using a liquid biopsy blood test, resu1
The Hospital Clínic launches an immunotherapy home infusion programme
The Hospital Clínic Medical Oncology Service, led by Dr. Aleix Prat, has launched a home infusion programme for solid organ cancer patients and immun1
A study explains how chemotherapy works in young women with low-risk hormone-sensitive breast cancer
Researchers from Hospital Clínic-IDIBAPS have shown for the first time that the benefit of chemotherapy in premenopausal patients with low-risk hormo1
Launch of a pioneering clinical trial to validate the efficacy of immunotherapy in 29 types of tumour
The ACROPOLI clinical trial is being launched. It is a pioneering, nationwide research study that aims to assess the efficacy of immunotherapy in 291
A molecular classification predicts the prognosis and the benefit of a cell cycle inhibitor in metastatic breast cancer
In a study published in the Journal of Clinical Oncology, researchers from the Hospital Clínic-IDIBAPS-UB and SOLTI showed the predictive capacity of1
EuCanImage: Next-generation artificial intelligence in oncology
Reserachers of Hospital Clínic-IDIBAPS participate in EuCanImage, a project from the Horizon 2020 program that will build a federated and scalable ca1
Spin-off Reveal Genomics born to develop innovative diagnostic tests in oncology
Reveal Genomics’ first goal will be to develop diagnostic tools based on complex genomic data for patients with advanced breast cancer.